These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 35402441)

  • 1. Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study.
    Zhou B; Peng C; Li L; Liu R; Zhu L; Chen X; Li J
    Front Med (Lausanne); 2022; 9():838030. PubMed ID: 35402441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
    Li CY; Chen S; Qian WL; Yang L; Zheng Q; Chen AJ; Chen J; Huang K; Fang S; Wang P; Hu L; Liu XR; Zhao XQ; Tan N; Cai T
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Oct; 57(10):1590-1595. PubMed ID: 37859375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice.
    Jang DH; Heo SJ; Jung HJ; Park MY; Seo SJ; Ahn J
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32599878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
    Simpson EL; Lockshin B; Lee LW; Chen Z; Daoud M; Korotzer A
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):261-270. PubMed ID: 38175364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
    Wang JY; Zhou BJ; Cao QZ; Peng C; Chen ML; Chen X; Li J
    Zhonghua Yi Xue Za Zhi; 2024 Aug; 104(30):2810-2816. PubMed ID: 39085148
    [No Abstract]   [Full Text] [Related]  

  • 6. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register.
    Alexander H; Malek R; Prieto-Merino D; Gribaleva E; Baden M; Beattie P; Brown S; Burton T; Cameron S; Coker B; Cork MJ; Hearn R; Ingram JR; Irvine AD; Johnston GA; Lambert A; Lunt M; Man I; Newell L; Ogg G; Patel P; Wan M; Warren RB; Woolf R; Yiu ZZN; Reynolds N; Ardern-Jones MR; Flohr C
    Br J Dermatol; 2024 Nov; 191(6):988-999. PubMed ID: 39044673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
    Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
    Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
    J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of dupilumab in adults with moderate and severe atopic dermatitis in Colombia: Real-life experience.
    Londoño J; Perez L; Moreno S; Chapman E; Garcia MB; Celis AM; Muñoz MA; Castillo D; Sánchez J; Arevalo Y; Lozano A; Alvis-Zakzuk NJ; Muñoz C; Botero L; Beltran C; García E
    World Allergy Organ J; 2023 Apr; 16(4):100763. PubMed ID: 37091550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience.
    Ferrucci S; Casazza G; Angileri L; Tavecchio S; Germiniasi F; Berti E; Marzano AV; Genovese G
    J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32183179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.
    Yosipovitch G; de Bruin-Weller M; Armstrong A; Wu JJ; Herranz P; Thaçi D; Delevry D; Bagousse GB; Zhang R; Shumel B; Rossi AB; Chao J
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2147-2157. PubMed ID: 34714527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world.
    Jang DH; Heo SJ; Kook HD; Lee DH; Jung HJ; Park MY; Ahn J
    Sci Rep; 2021 Dec; 11(1):23539. PubMed ID: 34876623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
    Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
    Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.
    Torres T; Sohrt Petersen A; Ivens U; Bosch Vilaro A; Stinson J; Carrascosa JM
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):983-992. PubMed ID: 38613642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dupilumab plus topical tacrolimus for atopic dermatitis in 6- to 12-year-old patients.
    Gao SS; Chen M; Wang R; Chen JG
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):9830-9837. PubMed ID: 37916349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of dupilumab in adult atopic dermatitis in Singapore.
    Yew YW; Zhao X; Yong AMY
    Singapore Med J; 2024 Jan; ():. PubMed ID: 38189411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types.
    Bosma AL; Ouwerkerk W; Heidema MJ; Prieto-Merino D; Ardern-Jones MR; Beattie P; Brown SJ; Ingram JR; Irvine AD; Ogg G; Patel P; Reynolds NJ; Hearn RMR; Wan M; Warren RB; Woolf RT; Hyseni AM; Gerbens LAA; Spuls PI; Flohr C; Middelkamp-Hup MA;
    JAAD Int; 2023 Mar; 10():14-24. PubMed ID: 36387062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Dupilumab in Children 6 Months to 11 Years Old With Atopic Dermatitis: A Retrospective Real-World Study in China.
    Yang N; Ye Y; Shao J; Wu H; Xu Q; Zhu J; Liu J; Li Z
    Dermatitis; 2024; 35(S1):S39-S46. PubMed ID: 36800177
    [No Abstract]   [Full Text] [Related]  

  • 19. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
    Kamphuis E; Boesjes CM; Loman L; Bakker DS; Poelhekken M; Zuithoff NPA; Kamsteeg M; Romeijn GLE; van Wijk F; de Bruin-Weller MS; de Graaf M; Schuttelaar MLA
    Pediatr Allergy Immunol; 2022 Dec; 33(12):e13887. PubMed ID: 36564878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable Clinical Response.
    Lee Y; Kim ME; Nahm DH
    Allergy Asthma Immunol Res; 2021 Sep; 13(5):733-745. PubMed ID: 34486258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.